Judit Kuhn, MD
Critical Care Medicine · Raleigh, NCNPI 1962721985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by GSK at 29.0% of the total. Reporting peaked in 2020 at $282 and has fallen 73.4% since, to $75 in 2024.
Across 72 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$287
- Boehringer Ingelheim$238
- AstraZeneca$175
- Sanofi$62
- Mylan Specialty L.p.$52
- Masimo Corporation$43
- plus $135 from 6 others
What the payments were for
- Food & beverage$96697%
- Education$253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 24 | $287 |
| Boehringer Ingelheim | 12 | $238 |
| AstraZeneca | 11 | $175 |
| Sanofi | 3 | $62 |
| Mylan Specialty L.p. | 3 | $52 |
| Masimo Corporation | 1 | $43 |
| United Therapeutics Corporation | 11 | $29 |
| Inogen, Inc. | 2 | $28 |
| Abiomed | 1 | $27 |
| AbbVie | 2 | $24 |
| Merck | 1 | $16 |
| Philips North America LLC | 1 | $12 |
How this compares
$991 in reported general payments places this provider in the 70th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 168 | $122,271 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $35,254 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $16,349 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $13,562 |
| Pirfenidone | 13 | $9,726 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $9,190 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $6,684 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $2,927 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $1,636 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $677 |
| MethotrexateMethotrexate Sodium | 18 | $345 |
| Azithromycin | 32 | $231 |
| Omeprazole | 15 | $198 |
| Prednisone | 46 | $160 |
| Montelukast Sodium | 15 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $287 | $173,875264 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $175 | $15,87544 claims |
| Boehringer IngelheimStiolto Respimat | $238 | $13,56216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Raleigh
- Daniel FoxRaleigh$133K
- Andrea MacdonaldRaleigh$67K
- Stephenie MannsRaleigh$17K
- Samer Taj-EldinRaleigh$1K
- Puneet AgarwalRaleigh$803
- Alexis SmithHuntersville$726K
- Rabih BecharaCharlotte$453K
- Ashish KhannaWinston Salem$364K
- Alan HeffnerCharlotte$326K
- Daniel FeinsteinPinehurst$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.